Nuvalent (NASDAQ: NUVL) to release topline ALKOVE-1 trial data for neladalkib in advanced ALK-positive NSCLC on November 17

Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by clinically validated kinase targets, is set to present topline pivotal data for its investigational ALK-selective inhibitor, neladalkib, on November 17, 2025. The announcement relates to the global Phase 1/2 ALKOVE-1 clinical trial, focused on patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have progressed after treatment with earlier-generation tyrosine kinase inhibitors (TKIs).

The webcast and conference call are scheduled for 8:00 a.m. Eastern Time, and will be closely watched by investors, analysts, and oncology stakeholders. Nuvalent confirmed that a live video webcast and slide presentation will be accessible via the investor section of its corporate website, with a replay available for 30 days.

This event is expected to be a critical inflection point in Nuvalent’s pipeline progress, offering insight into how neladalkib performs in a heavily pre-treated population where resistance mutations and brain metastases remain key treatment challenges.

What makes neladalkib’s design different from other ALK inhibitors?

Neladalkib is a next-generation, brain-penetrant ALK-selective tyrosine kinase inhibitor designed specifically to address the limitations of currently approved ALK inhibitors. These limitations include loss of efficacy due to resistance mutations, suboptimal central nervous system (CNS) penetration, and off-target toxicity arising from the inhibition of other kinases such as the tropomyosin receptor kinase (TRK) family.

Nuvalent’s development strategy for neladalkib has focused on ensuring sustained target engagement even in the presence of single or compound ALK mutations, particularly the G1202R mutation, which is among the most challenging for current treatments. The molecule’s selective design also avoids TRK inhibition, thereby minimizing the risk of CNS-related adverse effects that are sometimes observed in dual ALK/TRK inhibitors. This combination of selectivity and CNS exposure positions neladalkib as a potential best-in-class agent for patients with relapsed or refractory ALK-positive NSCLC.

According to experts tracking targeted lung cancer therapies, neladalkib’s pharmacological profile may support deeper and longer-lasting responses across multiple lines of therapy, including in patients with brain metastases, who often experience limited options after failure of first- and second-generation agents.

What is the scope and registrational intent of the ALKOVE-1 clinical trial?

The ALKOVE-1 study (ClinicalTrials.gov Identifier: NCT05384626) is Nuvalent’s global, first-in-human Phase 1/2 clinical trial for patients with ALK-positive NSCLC and other ALK-altered solid tumors. The Phase 1 dose-escalation portion of the trial has already been completed and evaluated key parameters including safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Importantly, this phase also established the recommended Phase 2 dose (RP2D) for subsequent expansion.

The ongoing Phase 2 portion is a single-arm, open-label study with registrational intent. It is enrolling patients with advanced ALK-positive NSCLC who have previously been treated with at least one ALK tyrosine kinase inhibitor. The design aligns with regulatory precedents for targeted therapies in biomarker-defined oncology indications, particularly where unmet medical needs and limited treatment alternatives exist.

In addition to the NSCLC cohorts, global enrollment continues in ALKOVE-1 for adolescent and adult patients with other ALK-positive solid tumors. This reflects Nuvalent’s broader ambition to expand neladalkib’s utility across multiple indications where ALK rearrangements are oncogenic drivers.

Neladalkib has already secured breakthrough therapy designation from the United States Food and Drug Administration for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have received two or more prior ALK TKIs. It also holds orphan drug designation in the same indication.

Which neladalkib efficacy and safety metrics could become the key stock drivers post-ALKOVE-1 data release?

The November 17 data release is widely regarded as one of Nuvalent’s most anticipated catalysts of 2025. Buy-side and sell-side stakeholders are expected to evaluate the dataset across several key dimensions, including objective response rate (ORR), duration of response (DoR), and intracranial efficacy, given the high incidence of CNS metastases in the ALK-positive NSCLC population.

Safety and tolerability will be another critical focus area. In particular, investors will be watching closely for any signs of dose-limiting toxicity or neurocognitive side effects, which have limited the broader adoption of other CNS-penetrant ALK inhibitors like lorlatinib. Neladalkib’s design explicitly avoids TRK inhibition, which may support a cleaner CNS adverse event profile.

From an institutional sentiment perspective, Nuvalent’s differentiated approach to structure-based drug design and its narrow focus on kinase resistance mutations have earned it considerable goodwill. Analysts from several major healthcare-focused investment firms have noted the pipeline’s clinical logic and its potential to offer best-in-class profiles in both ALK and ROS1-mutated cancers.

As of November 14, shares of Nuvalent, Inc. were trading around the USD 65 mark, showing steady movement over the past week. Investor positioning ahead of the data suggests cautious optimism, with moderate options activity and increased institutional interest flagged in recent 13F filings.

How does Nuvalent’s strategy compare to legacy and next-gen ALK inhibitor programs?

The ALK-positive NSCLC treatment landscape has evolved significantly over the past decade. First-generation inhibitor crizotinib set the stage, followed by second-generation agents like alectinib and brigatinib, which demonstrated improved CNS penetration and better activity against resistance mutations. Lorlatinib, a third-generation ALK inhibitor, offered further improvements in intracranial efficacy but brought new challenges in terms of side effect profile.

Nuvalent’s neladalkib is attempting to push the boundary even further by combining mutation coverage, CNS activity, and tolerability in a single molecule. This trifecta is considered essential for success in heavily pre-treated patients who have exhausted prior ALK-targeted therapies and often present with multiple resistance mutations and brain involvement.

Analysts following the precision oncology space believe that neladalkib, if the data holds, could not only gain traction in the post-lorlatinib setting but may eventually be positioned earlier in the treatment sequence. This would likely depend on future head-to-head studies or real-world evidence comparing long-term durability and safety across generations of ALK inhibitors.

What comes next in Nuvalent’s broader pipeline and regulatory roadmap?

Beyond ALKOVE-1, Nuvalent is developing a parallel portfolio of kinase-selective inhibitors that includes candidates targeting ROS1 fusion-positive NSCLC and HER2 alterations. The ROS1 program is designed to overcome the G2032R resistance mutation, another challenge in targeted lung cancer, while HER2 programs are aimed at kinase-driven tumors with central nervous system involvement.

Nuvalent’s drug discovery platform is grounded in deep expertise in structure-guided design and covalent chemistry, allowing it to create small molecules that selectively inhibit oncogenic kinases while avoiding structurally related off-targets. This design philosophy underpins the company’s ambition to build a robust pipeline capable of addressing tumor heterogeneity and resistance evolution.

With regulatory engagement likely following the ALKOVE-1 data release, Nuvalent may explore accelerated approval pathways. Investors will also watch for updates on potential partnerships or commercial buildout activities should neladalkib achieve positive readout and move toward filing.

What are the key takeaways from Nuvalent’s ALKOVE-1 trial timing and neladalkib pipeline strategy?

• Nuvalent, Inc. (NASDAQ: NUVL) will release topline pivotal data for neladalkib from the Phase 2 ALKOVE-1 trial on November 17, 2025, via webcast at 8:00 a.m. ET.
• The trial evaluates neladalkib in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer, with registrational intent.
• Neladalkib is a brain-penetrant, ALK-selective tyrosine kinase inhibitor designed to address resistance mutations like G1202R and avoid TRK-related CNS side effects.
• The molecule has received U.S. Food and Drug Administration breakthrough therapy and orphan drug designations for ALK-positive NSCLC.
• Analysts expect investors to focus on response rate, duration of response, intracranial activity, and CNS safety profile during the data presentation.
• Nuvalent’s precision oncology pipeline also includes programs targeting ROS1 and HER2-altered cancers, with upcoming milestones in 2026.
• Institutional sentiment remains constructive, supported by the company’s structure-based drug design strategy and clean resistance-targeted profiles.
• Shares of Nuvalent were trading around USD 65 ahead of the data, with moderate institutional buildup and options activity noted.
• If the data meet expectations, analysts believe Nuvalent may pursue accelerated approval discussions with regulatory authorities.
• The webcast and slide presentation will be archived on Nuvalent’s investor relations site for 30 days following the event.